SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology (MU) is experiencing a massive rally driven by an AI-induced memory chip shortage and significant analyst upgrades, with the community actively debating whether the stock is undergoing a long-term structural re-rating or forming a dangerous bubble. Investors are heavily focused on the company's dominance in High Bandwidth Memory and the expectation of further price appreciation as memory demand continues to outpace supply.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing a powerful momentum-driven breakout following strong earnings, a record-setting launch backlog, and a strategic acquisition that solidifies its position as a major space infrastructure provider. The community is actively debating the company's valuation against sector peers, with many traders focusing on the stock's significant move toward triple digits as a pivotal moment for its growth trajectory.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing explosive momentum fueled by a reported preliminary chipmaking agreement with Apple, solidifying the stock's turnaround narrative as a key domestic foundry asset. Community discussion is heavily divided between retail investors celebrating a 'life-changing' rally and skeptical traders warning of a blow-off top driven by aggressive momentum chasing and unsustainable valuation metrics.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as retail traders grapple with extreme volatility and the relentless upward momentum of the semiconductor sector, with community discourse heavily split between those attempting to time a massive bubble pop and those warning against the severe risks of decaying leveraged instruments. Investors are actively debating the sustainability of AI-driven semiconductor valuations, while many express deep frustration over the persistent divergence between sector performance and broader economic indicators.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is surging as investors pile into memory chip suppliers, driven by explosive AI-induced demand for data center flash storage and unprecedented supply shortages. The community is actively debating the stock's parabolic trajectory and extreme valuation, with many traders closely monitoring for potential squeezes while debating whether the current rally represents long-term structural growth or a speculative bubble.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending heavily as investors speculate on a critical FDA regulatory decision regarding its sBLA submission, while widespread community excitement grows over the recent firing of FDA official Marty Makary. The community is actively discussing the potential for a massive short squeeze, with many stakeholders interpreting the news as a positive catalyst for future approvals and global expansion.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Multicloud Services and Apps & Cross Platform. The Multicloud Services segment includes public and private cloud managed services offerings, as well as professional services related to designing and building multicloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security and data services, as well as professional services related to designing and implementing application, security and data services. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology is trending due to a massive surge in volume and retail interest following a new memorandum of understanding with AMD to develop governed enterprise AI cloud infrastructure. While bullish traders are eyeing a potential breakout and short squeeze, the community is actively debating the durability of this momentum versus concerns over the company's long-term debt and the non-binding nature of the partnership.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant volatility and trading activity as the market reacts to positive regulatory momentum in the EU for its combination respiratory vaccine and ongoing developments in its oncology pipeline, specifically regarding mRNA-4359. Investors and community members are actively debating the company's long-term pivot toward cancer therapeutics versus its legacy vaccine business, while monitoring high short interest and potential squeeze dynamics ahead of upcoming clinical data readouts.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant buzz as traders monitor potential breakout levels, with the community closely tracking its performance against key resistance points. Interest remains high as investors debate the impact of broader market trends and ecosystem developments on the asset's next major move.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is facing significant downward pressure and intense community criticism following management's commentary on soft sales and the CEO's public remarks, which have overshadowed the company's earnings beat. Investors and the broader community are debating the company's leadership and long-term defensive appeal, with many now looking for potential technical support levels or institutional intervention.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AIM AIM just dropped strong Phase 2 data combining Ampligen with Merck &amp; Co.￼’s Keytruda in advanced ovarian cancer.

• 50% response rate — tumors shrinking or disappearing in half the patients
• 32.5-month median survival — strong signal vs standard care
• Clean safety — no severe toxicities

Keytruda = immune “soldier,” Ampligen = “flare” exposing tumors.

Stock dip (~$0.36) is from a $4.2M warrant raise (~9M shares at $0.48) = short-term dilution, not science.

Big picture: Merck-backed oncology signal + strong data = rerating potential once financing noise clears.

My average .37 

Tags: $MRK $PFE $BMY

Le Ghoast

Teleboy

$AIM $BMY $MRK $PFE 

AIM didn’t raise cash because the trial failed — they raised it because the results were strong enough to keep pushing forward. The 50% response rate with Merck’s Keytruda gave them a real path toward bigger Phase 3 trials and eventually FDA approval.

The $4.2M raise gives AIM breathing room to finish collecting survival data, advance the pancreatic cancer program, and keep operations moving. The market focused on dilution from the $0.48 offering, which temporarily capped the stock reaction, but big investors wouldn’t be locking in millions around $0.48–$0.60 if they didn’t see upside ahead.

StockTwits for iOS

Lynker

AIM ImmunoTech

Merck & Co Inc

Pfizer Inc

Bristol-Myers Squibb Co.

 AIM just dropped strong Phase 2 data combining Ampligen with Merck & Co.￼’s Keytruda in advanced ovarian cancer.

• 50% response rate — tumors shrinking or disappearing in half the patients
• 32.5-month median survival — strong signal vs standard care
• Clean safety — no severe toxicities

Keytruda = immune “soldier,” Ampligen = “flare” exposing tumors.

Stock dip (~$0.36) is from a $4.2M warrant raise (~9M shares at $0.48) = short-term dilution, not science.

Big picture: Merck-backed oncology signal + strong data = rerating potential once financing noise clears.

My average .37 

Tags: 

StockTwits Web

@GordoHLYK13 do they need to raise cash for this trial done?

StockTwits For Android 

 do they need to raise cash for this trial done?

Cyrus

@CyrusTrade AIM didn’t raise cash because the trial failed — they raised it because the results were strong enough to keep pushing forward. The 50% response rate with Merck’s Keytruda gave them a real path toward bigger Phase 3 trials and eventually FDA approval.

The $4.2M raise gives AIM breathing room to finish collecting survival data, advance the pancreatic cancer program, and keep operations moving. The market focused on dilution from the $0.48 offering, which temporarily capped the stock reaction, but big investors wouldn’t be locking in millions around $0.48–$0.60 if they didn’t see upside ahead.

 AIM didn’t raise cash because the trial failed — they raised it because the results were strong enough to keep pushing forward. The 50% response rate with Merck’s Keytruda gave them a real path toward bigger Phase 3 trials and eventually FDA approval.

The $4.2M raise gives AIM breathing room to finish collecting survival data, advance the pancreatic cancer program, and keep operations moving. The market focused on dilution from the $0.48 offering, which temporarily capped the stock reaction, but big investors wouldn’t be locking in millions around $0.48–$0.60 if they didn’t see upside ahead.